{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-166018","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2023-06-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.420200+00:00","generated_at":"2026-06-14T02:12:29.891164+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.05,"calibrated_materiality_score":0.05,"confidence":"high","headline":"Mirum Pharmaceuticals announces results of 2023 annual meeting of stockholders","bullets":["Elected Lon Cardon, William Fairey, and Timothy Walbert as Class I directors to serve until 2026.","Each director received overwhelming support: Cardon 30.6M for, Fairey 30.4M for, Walbert 27.5M for.","Ratified Ernst & Young as independent auditor for FY 2023 with 34.2M votes for, 3.4K against.","Total shares outstanding and entitled to vote: 38,030,661 as of record date April 17, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-166018","json":"https://secwatch.observer/filing/0001193125-23-166018.json","markdown":"https://secwatch.observer/filing/0001193125-23-166018.md","text":"https://secwatch.observer/filing/0001193125-23-166018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523166018/0001193125-23-166018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523166018/d522261d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T02:12:29.891164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"55752a718b96a0ece13f6d407cd4d25a2664edae","claim":"Mirum Pharmaceuticals, Inc. shareholders approved Election of Directors at the 2023-06-12 meeting.","evidence_excerpt":"Proposal 1. Election of Directors The Company’s stockholders elected the three persons listed below as Class I directors, each to serve until the Company’s 2026 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified. The final voting results are as follows: Votes For Votes Withheld Broker Non-Votes Lon Cardon 30,587,478 410,063 3,228,927 William Fairey 30,362,034 635,507 3,228,927 Timothy Walbert 27,482,518 3,515,023 3,228,927","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523166018/0001193125-23-166018-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-12"}],"fact_type":"shareholder_vote"},{"claim_id":"b1dc11fe746463f5dba3a1d0d069817e476a19d2","claim":"Mirum Pharmaceuticals, Inc. shareholders approved Ratification of the Selection of Independent Registered Public Accounting Firm at the 2023-06-12 meeting.","evidence_excerpt":"Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. The final voting results are as follows: Votes For Votes Against Abstentions Broker Non-Votes 34,194,852 3,376 28,240","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1759425/000119312523166018/0001193125-23-166018-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-12"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}